Shoamanesh, Ashkan http://orcid.org/0000-0002-2802-1626
Cassarly, Christy
Morotti, Andrea
Romero, Javier M.
Oliveira-Filho, Jamary
Schlunk, Frieder
Jessel, Michael
Butcher, Kenneth
Gioia, Laura
Ayres, Alison
Vashkevich, Anastasia
Schwab, Kristin
Afzal, Mohammad Rauf
Martin, Renee H.
Qureshi, Adnan I.
Greenberg, Steven M.
Rosand, Jonathan
Goldstein, Joshua N.
,
Funding for this research was provided by:
National Institute of Neurological Disorders and Stroke (R01NS073344, U01-NS062091)
Article History
Received: 4 September 2020
Accepted: 9 April 2021
First Online: 22 July 2021
Source of support
: Supported by grants (National Institutes of Health - National InstituteĀ of Neurological Disorders and Stroke (NINDS) R01NS073344, to Dr. Rosand and U01-NS062091, to Dr. Qureshi). Chiesi USA and Astellas Pharma supplied intravenous nicardipine for use during the trial but had no other role in the design or conduct of the ATACH-2 trial or in this analysis/article. The National Institutes of Health, Chiesi USA, and Astellas Pharma had no involvement in the design, analyses, interpretation, or drafting of this report.
: The authors declare no conflicts of interest.
: The ATACH-2 protocol and consent forms were approved by the institutional review board or equivalent ethics committee at each participating site, and all participants or their legally authorized representative provided written informed consent.